The Food and Drug Administration (FDA) approved abemaciclib in combination with ET as adjuvant treatment for HR+/HER2− esBC, specifically for patients with at least N2 disease, or N1 disease with tumor size (T) of ≥3 or grade 3 features, and a Ki-67 index of ≥20%. This evidence concerns the gene MKI67 and neoplasm.